Anti Human-Papillomavirus vaccines: concepts, aims and trials;Vaccination anti-Papillomavirus Humains : principes et état d'avancement

Revue de Medecine Interne

Volumn 28, Issue 1, 2007, Pages 22-27

  Bourgault Villada, I ^a,b,c,d,e,f  

^a Institut Cochin   (France)

^b INSERM   (France)

^c INSTITUT COCHIN   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e HÔPITAL AMBROISE PARÉ   (France)

^f LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

cervical cancer; Cervical intraepithelial neoplasia; Human Papillomaviruses; Vaccination

Indexed keywords

BCG VACCINE; HEAT SHOCK PROTEIN; PLACEBO; WART VIRUS VACCINE;

ANTIBODY TITER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONDYLOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERYTHEMA; GENOTYPE; HUMAN; INJECTION SITE REACTION; KERATINOCYTE; PATHOPHYSIOLOGY; SEXUAL BEHAVIOR; SHORT SURVEY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS INFECTION; VIRUS LIKE AGENT; VIRUS ONCOGENE; WART VIRUS;

HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 33846232166     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2006.09.025     Document Type: Short Survey

References (37)

1. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl. Cancer Inst. 87 (1995) 796-802
2. Steinbrook R. The potential of human papillomavirus vaccines. N. Engl. J. Med. 354 (2006) 1109-1112
3. Hanz S., Alain S., and Denis F. Vaccins anti-papillomavirus et prévention du cancer du col de l'utérus. Presse Med. 34 (2005) 745-753
4. Boulanger J.C., Sevestre H., Bauville E., Ghighi C., Harlicot J.P., and Gondry J. Épidémiologie de l'infection à HPV. Gynecol. Obstet. Fertil. 32 (2004) 218-223
5. Clavel C., Masure M., Bory J.P., Putaud I., Mangeonjean C., Lorenzato M., et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br. J. Cancer 84 (2001) 1616-1623
6. Moscicki A.B., Shiboski S., Hills N.K., Powell K.J., Jay N., Hanson E.N., et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 364 (2004) 1678-1683
7. Carter J.J., Koutsky L.A., Hughes J.P., Lee S.K., Kuypers J., Kiviat N., et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J. Infect. Dis. 181 (2000) 1911-1919
8. Kirnbauer R., Hubbert N.L., Wheeler C.M., Becker T.M., Lowy D.R., and Schiller J.T. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J. Natl. Cancer Inst. 86 (1994) 494-499
9. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
10. Harro C.D., Pang Y.Y., Roden R.B., Hildesheim A., Wang Z., Reynolds M.J., et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93 (2001) 284-292
11. Evans T.G., Bonnez W., Rose R.C., Koenig S., Demeter L., Suzich J.A., et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J. Infect. Dis. 183 (2001) 1485-1493
12. Brown D.R., Bryan J.T., Schroeder J.M., Robinson T.S., Fife K.H., Wheeler C.M., et al. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. J. Infect. Dis. 184 (2001) 1183-1186
13. Emeny R.T., Wheeler C.M., Jansen K.U., Hunt W.C., Fu T.M., Smith J.F., et al. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J. Virol. 76 (2002) 7832-7842
14. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347 (2002) 1645-1651
15. Mao C., Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Wiley D.J., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol. 107 (2006) 18-27
16. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
17. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6 (2005) 271-278
18. van Driel W.J., Ressing M.E., Kenter G.G., Brandt R.M., Krul E.J., van Rossum A.B., et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur. J. Cancer 35 (1999) 946-952
19. Ressing M.E., van Driel W.J., Brandt R.M., Kenter G.G., de Jong J.H., Bauknecht T., et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J. Immunother. 23 (2000) 255-266
20. Steller M.A., Gurski K.J., Murakami M., Daniel R.W., Shah K.V., Celis E., et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin. Cancer Res. 4 (1998) 2103-2109
21. Steller M.A. Cervical cancer vaccines: progress and prospects. J. Soc. Gynecol. Investig. 9 (2002) 254-264
22. Muderspach L., Wilczynski S., Roman L., Bade L., Felix J., Small L.A., et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res. 6 (2000) 3406-3416
23. Borysiewicz L.K., Fiander A., Nimako M., Man S., Wilkinson G.W., Westmoreland D., et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347 (1996) 1523-1527
24. Kaufmann A.M., Stern P.L., Rankin E.M., Sommer H., Nuessler V., Schneider A., et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin. Cancer Res. 8 (2002) 3676-3685
25. Davidson E.J., Boswell C.M., Sehr P., Pawlita M., Tomlinson A.E., McVey R.J., et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res. 63 (2003) 6032-6041
26. Corona Gutierrez C.M., Tinoco A., Navarro T., Contreras M.L., Cortes R.R., Calzado P., et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum. Gene Ther. 15 (2004) 421-431
27. Garcia-Hernandez E., Gonzalez-Sanchez J.L., Andrade-Manzano A., Contreras M.L., Padilla S., Guzman C.C., et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther. 13 (2006) 592-597
28. Garcia F., Petry K.U., Muderspach L., Gold M.A., Braly P., Crum C.P., et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol. 103 (2004) 317-326
29. Klencke B., Matijevic M., Urban R.G., Lathey J.L., Hedley M.L., Berry M., et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin. Cancer Res. 8 (2002) 1028-1037
30. Palefsky J.M., Berry J.M., Jay N., Krogstad M., Da Costa M., Darragh T.M., et al. A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS 20 (2006) 1151-1155
31. Adams M., Borysiewicz L., Fiander A., Man S., Jasani B., Navabi H., et al. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 19 (2001) 2549-2556
32. Ferrara A., Nonn M., Sehr P., Schreckenberger C., Pawlita M., Durst M., et al. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J. Cancer Res. Clin. Oncol. 129 (2003) 521-530
33. Santin A.D., Bellone S., Palmieri M., Ravaggi A., Romani C., Tassi R., et al. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol. Oncol. 100 (2006) 469-478
34. Zhang L.F., Zhou J., Chen S., Cai L.L., Bao Q.Y., Zheng F.Y., et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 18 (2000) 1051-1058
35. Thompson H.S., Davies M.L., Holding F.P., Fallon R.E., Mann A.E., O'Neill T., et al. Phase I safety and antigenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts. Vaccine 17 (1999) 40-49
36. Lacey C.J., Thompson H.S., Monteiro E.F., O'Neill T., Davies M.L., Holding F.P., et al. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J. Infect. Dis. 179 (1999) 612-618
37. Vandepapeliere P., Barrasso R., Meijer C.J., Walboomers J.M., Wettendorff M., Stanberry L.R., et al. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J. Infect. Dis. 192 (2005) 2099-2107